LMP2-DC Vaccine Elicits Specific EBV-LMP2 Response to Effectively Improve Immunotherapy in Patients with Nasopharyngeal Cancer  

作　　者：ZENG Yi SI Yong Feng LAN Gui Ping WANG Zhan ZHOU Ling TANG Min Zhong SJ O`Brien LAN Jiao ZHOU Xiang Yang WANG Yong Li TANG Juan ZHOU Zhi Xiang DU Hai Jun LIN Hui 

机构地区：[1]State Key Laboratory for Infectious Disease Prevention and Control,National Institute of Viral Disease Control and Prevention,Chinese Center for Disease Control and Prevention,Beijing 102206,China [2]People's Hospital of Guangxi Zhuang Autonomous Region,Nanning 530021,Guangxi,China [3]Cancer center,Wuzhou Red Cross Hospital,Wuzhou 543002,Guangxi,China [4]Guy Harvey Oceanographic Center,Halmos College of Natural Sciences and Oceanography,Nova Southeastern University,Florida 33004,USA [5]College of Life Science and Bioengineering,Beijing University of Technology,Beijing 100124,China

出　　处：《Biomedical and Environmental Sciences》2020年第11期849-856,共8页生物医学与环境科学（英文版）

基　　金：Mega Project of Research on the Prevention and Control of HIV/AIDS,Viral Hepatitis Infectious Diseases[Grant No:2018ZX10102001];the Key Science and Technology Program of Guangxi Zhuang Autonomous Region[Grant No.14124003-3];the National High Technology Research and Development Program of China[Grant No.2007AA021107];and the National Basic Research Program of China[973 Program,Grant No.2011CB504800]。

摘　　要：Objective To evaluate the safety and effectiveness of a vaccine based on latent membrane protein 2(LMP2)modified dendritic cells(DCs)that boosts specific responses of cytotoxic T lymphocytes(CTLs)to LMP2 before and after intradermal injection in patients with nasopharyngeal carcinoma(NPC).Methods DCs were derived from peripheral blood monocytes of patients with NPC.We prepared LMP2-DCs infected by recombinant adenovirus vector expressing LMP2(rAd-LMP2).NPC patients were immunized with 2×105 LMP2-DCs by intradermal injection at week 0 and after the second and fourth weeks.Specific responses to LMP2 were detected by enzyme-linked immunospot(ELISPOT)assay at week 0 and at the fifth and eighth weeks.Local clinicians performed the follow-up and tracking of patients.Results We demonstrated that DCs derived from monocytes displayed typical DC morphologies;the expression of LMP2 in the LMP2-DCs vaccine was confirmed by immunocytochemical assay.Twenty-nine patients with NPC were enrolled in this clinical trial.The LMP2-DCs vaccine was well tolerated in all of the patients.Boosted responses to LMP2 peptide sub-pools were observed in 18 of the 29 patients with NPC.The follow-up data of 29 immunized patients from April,2010 to April 2015 indicated a five-year survival rate of 94.4%in responders and 45.5%in non-responders.Conclusion In this pilot study,we demonstrated that the LMP2-DCs vaccine is safe and effective in patients with NPC.Specific CTLs responses to LMP2 play a certain role in controlling and preventing the recurrence and metastasis of NPC,which warrants further clinical testing.

关 键 词：LMP2-DCs Nasopharyngeal carcinoma IMMUNOTHERAPY 

分 类 号：R739.63[医药卫生—肿瘤]